

Medicare Coverage Updated to Include the BRCA[®]Analysis[®] Large Rearrangement Test!

The BRCA[®]Analysis[®] Large Rearrangement Test (BART™) provides a way to detect large genomic rearrangements in *BRCA1* and *BRCA2* that are not identified as part of the BRCA[®]Analysis[®] sequencing test. **Large rearrangement mutations account for 6-10% of all Hereditary Breast and Ovarian Cancer (HBOC) mutations identified.**¹



As of October 1, 2012, the Medicare coverage policy states*:

“Comprehensive genetic testing of BRCA1 and BRCA2 includes full sequencing and detection of large genomic rearrangements.”



BART testing will be covered for Medicare patients meeting one of the criteria for *BRCA1/2* testing listed in the policy which is summarized below. The complete medical policy may be accessed on-line via the link on www.myriadpro.com/medicarecriteria.

Patients with a personal history of breast cancer who:

- ▶ were diagnosed at or before age 45
- ▶ were diagnosed at or before age 50 or with two breast primaries and have either:
 - one or more close blood relative(s) with breast cancer at or before age 50, **OR**
 - one or more close blood relative(s) with epithelial ovarian/fallopian tube/primary peritoneal cancer
- ▶ were diagnosed with two primary breast cancers, the first of which occurred prior to age 50
- ▶ were diagnosed before age 60 with a triple negative breast cancer (ER-, PR-, HER2-)
- ▶ were diagnosed before age 50 with a limited family history[†]
- ▶ were diagnosed at any age, with either:
 - two or more close blood relatives with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer, at any age, **OR**
 - a close male blood relative with breast cancer
- ▶ are of Ashkenazi Jewish descent
- ▶ have a close relative with a known *BRCA1* or *BRCA2* gene mutation

Patients with a personal history of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Patients with a personal history of male breast cancer

The following items *must* be submitted with the patient's sample:

- Completed Test Request Form
- Copies of the patient's insurance card(s)
- Signed Informed Consent

If a patient does not meet criteria, a completed Advance Beneficiary Notice of Noncoverage (ABN) is required.

Please direct any questions regarding Myriad's testing services to your local Myriad Account Executive or call Customer Service at (800) 469-7423.

1. Judkins T, et al. Clinical Significance of Large Rearrangements in *BRCA1* and *BRCA2*. *Cancer* 2012 (Epub ahead of print).

*Subject to change without notice

[†]Defined as fewer than two first- or second-degree female relatives or female relatives surviving beyond 45 years in either lineage

BRCA[®]Analysis[®]

